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Background: Delirium is associated with substantial morbidity and mortality rates in elderly hospitalised patients, and a
growing problem due to increase in life expectancy. Implementation of standardised non-pharmacological delirium
prevention strategies is challenging and adherence remains low. Pharmacological delirium prevention with haloperidol,
currently the drug of choice for delirium, seems promising. However, the generalisability of randomised controlled trial
results is questionable since studies have only been performed in selected postoperative hip-surgery and intensive
care unit patient populations. We therefore present the design of the multicenter, randomised, double-blind,
placebo-controlled clinical trial on early pharmacological intervention to prevent delirium: haloperidol
prophylaxis in older emergency department patients (The HARPOON study).
Methods/Design: In six Dutch hospitals, at-risk patients aged 70 years or older acutely admitted through the emergency
department for general medicine and surgical specialties are randomised (n = 390) for treatment with prophylactic
haloperidol 1 mg or placebo twice daily for a maximum of seven consecutive days. Primary outcome measure is the
incidence of in-hospital delirium within seven days of start of the study intervention, diagnosed with the Confusion
Assessment Method, and the Diagnostic and Statistical Manual of Mental Disorders, fourth edition criteria for delirium.
Secondary outcome measures include delirium severity and duration assessed with the Delirium Rating Scale Revised 98;
number of delirium-free days; adverse events; hospital length-of-stay; all-cause mortality; new institutionalisation;
(Instrumental) Activities of Daily Living assessed with the Katz Index of ADL, and Lawton IADL scale; cognitive function
assessed with the Six-item Cognitive Impairment Test, and the Dutch short form Informant Questionnaire on Cognitive
Decline in the Elderly. Patients will be contacted by telephone three and six months post-discharge to collect data on
cognitive- and physical function, home residency, all-cause hospital admissions, and all-cause mortality.
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Discussion: The HARPOON study will provide relevant information on the efficacy and safety of prophylactic
haloperidol treatment for in-hospital delirium and its effects on relevant clinical outcomes in elderly at-risk
medical and surgical patients.
Trial registration: EudraCT Number: 201100476215; ClinicalTrials.gov Identifier: NCT01530308; Dutch Clinical
Trial Registry: NTR3207
Keywords: Haloperidol, Delirium, Prophylactic treatment, Older patientsBackground
Delirium is a serious and frequently occurring complication
of (acute) illness in older hospitalised patients with preva-
lence rates of more than 30% [1]. Delirium is a neuro-
psychiatric syndrome characterised by a disturbance of
consciousness which has an acute onset and fluctuating
course, typically developing within hours and lasting for
several days to weeks or even months [1-3].
In older patients, development of in-hospital delirium
is associated with a range of negative patient out-
comes such as increased hospital length-of-stay, long-term
cognitive- and functional decline, new institutionalisation,
and increased mortality [4-6], thereby also leading to sub-
stantial healthcare costs [7]. Because of the associated
healthcare and economic burden, multicomponent
non-pharmacological intervention strategies targeting
delirium risk factors in the hospital setting have been
introduced. Although they are effective in reducing de-
lirium incidence in elderly general medicine and surgi-
cal patients [8,9], their effectiveness seems largely to
depend on protocol adherence [10] which may be low due
to high staff workload. In addition, non-pharmacological
multicomponent hospital-based interventions do not seem
to affect post-discharge outcomes such as cognitive or func-
tional status, and nursing home placement [11]. Low-dose
haloperidol prophylaxis has been shown to lower delirium
incidence in older postoperative intensive care unit (ICU)
patients [12,13], and duration and severity in (mainly elect-
ive) hip-surgery patients [14]. However, the effect of halo-
peridol prophylaxis on in-hospital delirium development
and post-discharge outcomes in an older general medicine
and surgical patient population has not been studied yet.
This paper describes the design of the multicenter,
randomised, double-blind, placebo-controlled clinical
trial to evaluate the efficacy and safety of early prophy-
lactic treatment with low dose haloperidol on in-hospital
delirium, and post-discharge outcomes in acutely admit-




To study the differences in in-hospital seven-day delir-
ium incidence after acute admission for both generalmedicine and surgical specialties in older at-risk patients
treated early with prophylactic haloperidol or placebo.
Secondary outcome measures
Severity and duration of delirium; number of delirium-
free days; hospital length-of-stay; adverse events; all-
cause mortality in-hospital and within six months post-
discharge; cognitive and physical function at baseline,
three, and six months post-discharge; new institutionali-
sation post-discharge; number of hospital admissions
within six months post-discharge.
Study design
The HARPOON study is a multicenter, investigator
initiated, stratified randomised, double-blind, placebo-
controlled clinical trial with a six-month follow-up
period. The study design is demonstrated in Figure 1.
All at-risk patients aged 70 years or over presenting to
the emergency department (ED), admitted for general
medicine or surgical specialties will be screened for
predefined in- and exclusion criteria as described in
the section ‘Study population and recruitment’. In-
creased risk for developing delirium during hospital
admission will be assessed according to specific delir-
ium risk questions (Figure 2) based on the Dutch
Hospital Patient Safety Program (in Dutch: VMS Vei-
ligheidsprogramma [15]). This program was developed
to systematically improve patient safety on 10 priority
themes, which is now standardised hospital care in all
Dutch hospitals since 2013. One of these themes is
‘Vulnerable elderly’ [15], which aims to reduce avoid-
able loss of function caused by complications of
hospitalization and includes detection (risk assess-
ment), and implementation of prevention and inter-
vention measures for:
1. Malnutrition, including stimulation and
measurement of nutritional intake by nutrition
assistants, and dietary consultation;
2. Falls and mobility impairments, including adequate
footwear, stimulation of physical activity in or out of














Follow-up three and six months post-discharge
Questionnaires and registration of secondary outcome measures
Study intervention according 
to protocol
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Figure 1 Design of the HARPOON study.
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dardised hospital care covers identification and modulation
of precipitating delirium risk factors such as medication re-
views and orientation and noise-reduction measures, creat-
ing an optimal background regimen for conduction of this
trial in all participating hospitals. Patients who positively
confirm one or more of the VMS delirium risk questions
(VMS ≥1) are considered at-risk for developing delirium
during hospital admission. Patients with VMS 0 on first
evaluation are not eligible for this study. Eligible patients
will be asked for informed consent. In case of inability to
write, patients must provide verbal consent in the presence
of an independent witness (preferably patients’ proxy) who
may then sign the informed consent form. The study medi-
cation, haloperidol 1 mg or identical placebo tablets, will be
given orally to participants twice daily at 12 pm and 8 pm
for a maximum of seven consecutive days (14 treatment
dosages) on top of standardised care based on the imple-
mented VMS program ‘Vulnerable elderly’. During the
seven-day intervention period nursing staff will screenFigure 2 VMS delirium risk questions. Each positive answer values 1
point, a total score of 1 point or higher indicates the patient is at-risk for
in-hospital delirium.participants for delirium symptoms. Additionally, a trained
observer (physician or geriatric nurse) will daily visit partici-
pants to detect the presence of delirium, register potential
adverse events based on 24-hour nursing observations, clin-
ical judgement, and electrocardiogram (ECG) monitoring,
and to check for adherence to standardised adequate envir-
onmental manipulations for delirium such as orientation
measures. For patients who have not developed delirium
within seven days of initiation of the study intervention,
daily assessment stops. Patients who develop delirium are
evaluated daily by the observer to record delirium severity
and duration until symptoms diminish. Study drug admin-
istration is terminated early if a participant develops delir-
ium, is transferred to a non-participating care unit such as
the ICU, refuses further participation in the trial, the QTc
interval is more than 500 milliseconds (ms), is discharged
from the hospital, or dies within seven-day of initiation of
the study intervention. In case of established delirium or if
the assigned study intervention is thought to have a direct
influence on the patient’s treatment, the treating physician
will request for unblinding and may further decide on treat-
ment. For unblinding of treatment assignment, the treating
physician is able to contact the VUmc consultant pharma-
cist through a central telephone number 24 hours a day,
seven days a week.
This study is conducted according to the Declaration
of Helsinki. This trial is approved by the accredited
Medical Ethical Committee of VU University Medical
Center (VUmc) Amsterdam, the Netherlands (refer-
ence number: 2012.177). The executive boards of Isala
Hospital Zwolle, Spaarne Hospital Hoofddorp, Rijn-
land Hospital Leiderdorp, Jeroen Bosch Hospital’s
Hertogenbosch, and Medical Centre Alkmaar (MCA),
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feasibility approval.
Location and setting
This study is primarily conducted at VUmc, a 733-bed
teaching hospital located in Amsterdam, the Netherlands.
Secondary study locations include the Isala Hospital Zwolle
(976 beds), Spaarne Hospital Hoofddorp (455 beds),
Rijnland Hospital Leiderdorp (420 beds), Jeroen Bosch
Hospital ’s Hertogenbosch (730 beds), and MCA Alkmaar
(485 beds), the Netherlands.
Study population and recruitment
Inclusion criteria
Patients aged 70 years and over are eligible when acutely
admitted to the hospital through the ED for general
medicine or surgical specialties, are able to speak and
understand Dutch or English language, are at-risk for
delirium on admission (VMS ≥1), are available for inclu-
sion within 24 hours after admission, and are able to
provide informed consent. Patients are considered com-
petent to provide informed consent if – after having
spoken with the patient – the observer and/or the treat-
ing physician agree on the ability of the patient to under-
stand and/or recall relevant study information, including
the purpose of the study, its experimental nature, poten-
tial benefits and risks, the right to withdraw, and confi-
dentiality of collected data, and to make a voluntary
decision to participate. If their cognitive competence is
in question, the patient will be regarded as ineligible.
Exclusion criteria
Exclusion criteria for participation are delirium on ad-
mission according to the DSM-IV criteria; VMS 0; pa-
tients not able to take study medication according to
protocol (including nil per os); specific heart conditions
on admission including QTc interval of more than 500
ms, recent myocardial infarction, decompensated heart
failure, second- or third-degree AV block, (history of )
ventricular arrhythmias or Torsade de Pointes (TdP),
uncorrected hypokalemia with serum potassium level 3.0
milliequivalents per liter (mEq/L) or less, clinical signifi-
cant bradycardia; concomitant use of pharmacodynami-
cally interacting medication; use of antipsychotic or
dopaminergic drugs; use of QT prolonging drugs in the
presence of prolonged QTc interval (more than 450 ms
and 460 ms, for men and women respectively) on base-
line ECG; Parkinson’s Disease; Vascular or Lewy Body
Dementia; Hypokinetic Movement Disorder; (history of )
Neuroleptic Malignant Syndrome; Central Anticholinergic
Syndrome; substance abuse and dependence according to
the DSM-IV criteria; (history of) epilepsy; concomitant par-
ticipation in another clinical trial with the exception ofobservational studies; not competent to provide informed
consent.
Randomisation
Two well-known variables associated with increased risk
of delirium are age 80 years or over and surgical treat-
ment/anaesthesia. To balance population representatives
in both treatment groups, four strata are constructed
with separate randomisation schedules: (1) age 70 to 80
years, planned surgery on admission; (2) age 70 to 80
years, no planned surgery on admission; (3) age 80 years
or over, planned surgery on admission; (4) age 80 years
or over, no planned surgery on admission. Each stratum
consists of 20 pre-randomised individual study numbers,
10 assigned to haloperidol and 10 to placebo treatment,
prepared by the Central Pharmacy for The Hague Hos-
pitals (Apotheek Haagse Ziekenhuizen/AHZ located in
The Hague, the Netherlands). Participants, observers,
physicians, nurses, other care givers, at the investigative
sites are all blinded to the assigned intervention. The
VUmc clinical pharmacy holds the randomisation list.
Study interventions
AHZ is responsible for preparing, labelling, packaging
and distributing the study medication according to Good
Manufacturing Procedure (GMP) guidelines. Both the
haloperidol (as a verum) and placebo tablets are identi-
cal in appearance, have fixed concentrations of 1 mg per
tablet, and are packaged in identically labelled medicine
carton boxes. Study medication prescription is standar-
dised in every study centre’s automated prescription
system. On prescription by the local investigator(s), a
carton box containing study medication (either haloperi-
dol or placebo tablets) can be collected. To ensure study
medication access 24 hours a day, seven days a week,
medicine boxes are securely stored in the ED or on the
wards rather than in the local clinical pharmacy.
Data collection
Data will be mainly collected by two observers, a phy-
sician (EJMS) and geriatric nurse (AV) trained according
to the Good Clinical Practice (GCP) principles. Partici-
pants’ demographic data, medical history, (prescription)
medication history on admission (including the use of sleep
medication and antidepressants), presence of sleep-wake
cycle disturbances, visual and/or hearing impairment, sub-
stance use, and vital parameters will be documented. Med-
ical history and (prescription) medications will be coded
according to the World Health Organization’s International
Statistical Classification of Diseases and Related Health
Problems 10th revision (ICD-10) [16], and the Anatomical
Therapeutic Chemical (ATC) Classification System [17].
Severity and number of co-morbidities are listed according
to the Charlson comorbidity index using the ICD-10 coding
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Katz Index of Independence in Activities of Daily Living
(ADL) [20,21] and the Lawton Instrumental Activities of
Daily Living (IADL) scale [22]. The Six Item Cognitive
Impairment Test (6-CIT) is used to evaluate participants’
cognitive function [23-25]. Primary caregivers are asked to
complete the IQCODE-N in order to reflect on the partici-
pant’s cognitive function prior to hospitalisation [26]. The
Confusion Assessment Method (CAM) will be used to
diagnose delirium according to the Diagnostic and Statis-
tical Manual of Mental Disorders, Fourth edition (DSM-IV)
delirium criteria during the study intervention period, and
to ensure delirium is not present on study inclusion [27].
Nurses register the Delirium Observation Screening (DOS)
scale three times a day (once every day, evening and night
shift) during the intervention period to evaluate delirium
symptoms [28,29]. Once delirium is established, one of the
observers will perform the DRS-R-98 once-daily to assess
delirium severity and duration [30]. An ECG is performed
at baseline, after two and six treatment dosages, and at the
end of the intervention period to register QTc intervals.
ECG is repeated daily until a steady state is reached in case
of prolonged QTc interval (more than 450 ms and 460 ms,
for men and women respectively), or if the patient is taking
other QT prolonging medications. On study inclusion, and
at the time of ECG after study drug administration dose
six, a 4 ml blood sample is collected, and plasma is stored
at −80°C at the VUmc Clinical Pharmaceutical and Toxico-
logical Laboratory to determine haloperidol levels. On
discharge, the number of days spent in the hospital is
recorded.
Follow-up assessments
Three and six months after discharge, patients are con-
tacted by telephone by one of the observers to perform
the Katz ADL, the Lawton IADL scale, and the 6-CIT,
and to obtain data on home residency, hospital admis-
sions, (recurrent) delirium, and all-cause mortality.
Study monitoring
This study will be monitored by two members – the man-
ager and an independent clinical research assistant – of
the Clinical Research Unit, Department of Internal
Medicine, VUmc Amsterdam, the Netherlands. During
the monitoring visits at respectively the beginning,
half-way and end of the study, the consistency of data
collection, documentation and the presence and com-
pleteness of the Investigator Site File are checked for com-
pliance with GCP guidelines. Findings are systematically
recorded and signed by the monitors.
Data Safety Monitoring Board
Because this study is a pharmacological intervention study
recruiting (vulnerable) older patients, we appointed a DataSafety Monitoring Board (DSMB). The primary mandate of
the DSMB is to monitor patient safety during the trial. The
DSMB for this study consists of four independent mem-
bers: two emeritus professors of internal medicine, a profes-
sor of clinical epidemiology, and a consultant physician in
geriatric medicine. The DSMB reviews unblinded results
and convenes prior to the beginning of the study, and
thereafter, every six months from the first randomisation
date. On request, the DSMB may obtain unblinded study
results from the hospital pharmacy. When a study partici-
pant dies, the DSMB evaluates the event and mortality rates
in both study arms. After 125 patients have completed the
entire study period including follow-up in each study arm,
the DSMB will perform a safety interim analysis with re-
spect to all-cause mortality.
Sample size calculation
The primary study objective is to evaluate the effect of
prophylactic haloperidol compared to placebo for the in-
cidence of in-hospital delirium within seven days of start
of the study intervention. Based on previous studies, we
expect the incidence of delirium in our target patient
population currently to be 20%. Aiming for an absolute
reduction of 10% in the haloperidol intervention group,
with the significance level set at 5%, inclusion of n = 195
patients per study arm (390 patients in total) will give us
a power of 80% to detect differences with a two-sided
alpha of 0.05.
Statistics
For the data analysis IBM SPSS Statistics 20 will be used.
Clinical trial data will be primarily registered in paper
case report forms and later transcribed into the elec-
tronic data capture system of OpenClinica, open source
clinical trail software. The primary analysis is aimed at
evaluation of the primary outcome of this study: the in-
cidence of in-hospital delirium according to the DSM-IV
criteria in older at-risk patients aged 70 years or over
who are acutely admitted through the ED for a general
medicine or surgical specialty within seven days of initiation
of the study intervention. Data from all randomised pa-
tients will be analysed according to the Intention-to-treat
principal. The primary outcome delirium incidence is con-
sidered a binary outcome, present or absent. Patients who
for example leave the hospital (or die in-hospital) within
seven days of start of the study intervention without experi-
encing delirium will be regarded negative on the primary
outcome. Patients who do not complete the intervention
will be monitored during their in-hospital stay for occur-
rence of delirium. The number of patients diagnosed with
delirium at least once in the seven days following initiation
of the study intervention will be calculated for both the
haloperidol and placebo group, and subsequently this num-
ber is divided by the total amount of patients assigned to
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dence ratio within seven days of initiation of the study
intervention. Pearson’s chi-squared test will be used to
compare this number between the two groups. Continuous
normally distributed data including patient demographic
data will be tested with Student’s t test. The Mann–
Whitney U test is used for comparison of non-normal
distributed data such as secondary outcome measures
concerning efficacy of prophylactic haloperidol treatment.
Log rank test will be used to establish the time to (first)
delirium diagnosis (number of delirium-free days), which
will be compared between groups. Adverse events in both
groups will be globally described. Kaplan-Meier estimates
will be used to display survival probability within 6
months after hospital discharge for patients with and
without diagnosed in-hospital delirium.
Discussion
This stratified randomised, placebo-controlled, double-
blind clinical trial studies the efficacy and safety of halo-
peridol prophylaxis for prevention of delirium in older
at-risk patients aged 70 years or over who are acutely
admitted to the hospital through the ED for general
medicine or surgical specialties, because generalisability
of existing study results from well-designed RCTs in this
field are limited to postoperative (mainly elective) hip-
surgery [14] and ICU patients [13].
In general, in-hospital delirium occurs within three or
four days after admission or surgery [12,31], but the
mean time to onset may vary up to approximately six
days in ICU patients [13]. Because delirium severity and
duration amongst other things were chosen as secondary
outcome parameters, a study intervention-period was se-
lected that is long enough to also identify delirium de-
veloping under prophylactic haloperidol treatment.
Treatment response after initiation of haloperidol treat-
ment is to be expected within 24 to 48 hours after initi-
ation of therapy [32,33]. A small RCT in 47 hip surgery
patients aged 70 and older demonstrated that a haloperi-
dol treatment regimen of 1 mg three times daily was
more effective in reducing severity of established delir-
ium than 1.5 mg twice-daily or 3 mg once-daily (mean
highest DRS-R-98 score ± standard deviation of 15.8 ±
5.2, versus 21.3 ± 4.7, and 19.2 ± 6.1 respectively), while
duration of delirium tended to be shorter in the twice-
daily dosing group (2.3 ± 1.8 days, versus 3.9 ± 2.6 and
4.1 ± 1.9 days in the three times daily and once-daily
group respectively). No side effects were noted in the
total study population (total haloperidol dose 3 mg/day)
[34]. In a large placebo-controlled RCT in 430 hip sur-
gery patients aged 70 years and older, a three times daily
prophylactic regimen with haloperidol (total dose 1.5
mg/day, maximum intervention period six days) did not
significantly reduce postoperative delirium incidence inhip surgery patients, though it did significantly reduce
delirium severity (mean highest DRS-R-98 score 14.4 ±
3.4 versus 18.4 ± 4.3) and duration (5.4 versus 11.8 days,
95% CI = 2.0-5.8; p < 0.001) in the haloperidol compared
to the placebo group respectively [14]. Aforementioned
study results suggest that although a three times daily
dosing strategy with haloperidol seems superior in redu-
cing symptom severity in the treatment of established
delirium, it is not efficacious in reducing the incidence
of postoperative delirium when administered prophylac-
tic. Since the primary objective of this study is to investi-
gate the effect of prophylactic haloperidol administration
on delirium incidence in a broader elderly patient popu-
lation, a different treatment regimen of 1 mg haloperidol
or placebo twice-daily for a maximum intervention
period of seven consecutive days was chosen. In case of
established delirium, symptoms tend to fluctuate during
the course of the day with potential evening or night-
time worsening. Given that haloperidol peak plasma
concentrations occur within two to six hours after oral
administration, administration of the prophylactic study
intervention in the early afternoon and mid evening was
favoured. Capsule count of returned study medication in
addition to evaluation of nurse medication charts con-
firmed by plasma drug levels is used as a reliable method
of assessing study medication adherence in this clinical
trial [35].
In addition to extrapyramidal side effects, more rare
side effects as ventricular arrhythmia’s and TdP are a
great concern for physicians initiating haloperidol treat-
ment in a patient. To date, there are no consensus prac-
tice guidelines on QT(c) monitoring for the prevention
of TdP in the hospital setting, and recommendations are
primarily based on clinical experience [36-38]. During
this study routine ECG measurements will be performed
and plasma haloperidol levels will be determined to
evaluate individual QTc changes related to these halo-
peridol levels in order to expand the current knowledge
base.
Eligibility criteria include that a subject has the cogni-
tive capacity to understand the scope of the study and is
able to provide informed consent independently. Based
on the sample size calculation, a large numbers of sub-
jects must be screened. Therefore, a brief and valid
screening instrument was selected to assess cognitive
function (6-CIT) [24,25] on admission in a face-to-face
interview. The Dutch version of the 6-CIT has high
diagnostic accuracy compared with the cognitive impair-
ment criterion standard Mini-Mental State Examination
[23]. Although the 6-CIT has not been validated for tele-
phone administration, we considered it to be accurate
for use over the telephone given that it includes diagnos-
tic properties (e.g. temporal orientation, and object re-
call) similar to a six-item screener suitable for telephone
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liable way to collect data on ADL by telephone [40].
Telephone follow-up was chosen because it is safe and
more efficient than re-inviting subjects for a face-to-face
interview.
In conclusion, the HARPOON study is a well-designed
double-blind, placebo-controlled RCT that we believe
will provide relevant information on the efficacy and
safety of early administration of low-dose haloperidol for
preventing delirium in at-risk elderly patients in the hos-
pital setting, and its effects on post discharge outcomes.
The predicted study completion is May 1st 2015.
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